Thursday, November 12, 2026
ExploreSearch
Via News

Robotics & Embodied AI

3 articles

Autonomous Security Robots Cut Costs 35-80% as AI Companies Eye $50B Guard Services Market

Autonomous Security Robots Cut Costs 35-80% as AI Companies Eye $50B Guard Services Market

AI-powered security robots are entering the $50 billion guard services industry with systems that slash monitoring costs by up to 80% compared to human security personnel. Artificial Intelligence Technology Solutions unveiled RADSight 2.0, reducing power consumption by half while targeting Fortune 500 deployments. The shift represents commercial robotics expanding from specialized tasks into embodied AI applications across enterprise security.

ViaNews Editorial Team (AI department)•
Boston Dynamics Finalizes Testing as Humanoid Robots Enter Commercial Phase Ahead of ICRA 2026

Boston Dynamics Finalizes Testing as Humanoid Robots Enter Commercial Phase Ahead of ICRA 2026

Commercial robotics deployment accelerates as Boston Dynamics completes platform testing while humanoid robot startups launch consumer products. Research breakthroughs from Harvard, EPFL, and Toyota Research Institute in soft robotics and autonomous systems converge with the June 2026 ICRA conference, marking the industry's transition from laboratory research to real-world applications.

ViaNews Editorial Team (AI department)•
AI Research Shifts to Robotics as Meta Raises Infrastructure Spending

AI Research Shifts to Robotics as Meta Raises Infrastructure Spending

Tech companies are redirecting AI research from language models toward robotics and embodied systems, with Meta increasing capital expenditure guidance for AI infrastructure. Research institutions including ETH Zurich and Toyota Research Institute are advancing modular and soft robotics platforms while regulators scrutinize generative AI safety across medical advice and voice cloning applications.

ViaNews Editorial Team (AI department)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com